507115453 02/07/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7162293

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ALEXANDER SCHWARZ	01/12/2022

RECEIVING PARTY DATA

Name:	ELEUSIS THERAPEUTICS US, INC.
Street Address:	99 WALL STREET, #2205
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10005

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	17520275
Application Number:	63276096

CORRESPONDENCE DATA

Fax Number: (617)428-7045

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 428-0200

Email: patentadmin@clarkelbing.com

Correspondent Name: CLARK & ELBING LLP
Address Line 1: 101 FEDERAL STREET

Address Line 2: 15TH FLOOR

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	50971-044002, -044003
NAME OF SUBMITTER:	JEFFREY J. ELLISON, PH.D.
SIGNATURE:	/Jeffrey J. Ellison, Ph.D./
DATE SIGNED:	02/07/2022

Total Attachments: 3

source=50971-044002 and 50971-044003 - Assignment for Execution (Schwarz).DOC#page1.tif source=50971-044002 and 50971-044003 - Assignment for Execution (Schwarz).DOC#page2.tif source=50971-044002 and 50971-044003 - Assignment for Execution (Schwarz).DOC#page3.tif

507115453 PATENT REEL: 058909 FRAME: 0851

Attorney Docket Nos.: 50971-044002 50971-044003

ASSIGNMENT

For valuable consideration, I,

Full Name of Assignor	City	State (and Country if not USA)
Alexander SCHWARZ	Baltimore	Maryland

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address	
Eleusis Therapeutics US, Inc.	Delaware	99 Wall Street, #2205 New York, NY 10005	

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by me, identified as:

Title of Application	Filing Date	Serial Number
PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF	November 5, 2021	17/520,275
PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF	November 5, 2021	63/276,096

and I authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and I authorize the Assignee to apply in all countries in my name or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and I agree for me and my respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

Attorney Docket Nos.: 50971-044002 50971-044003

ـــــــر DocuSigned by:		50971-04400
Alex Schware	12-Jan-2022	
Signature	Date	
Alexander SCHWARZ		
Witness:		
Signature	Date	
Printed name		

Printed name

RECORDED: 02/07/2022

In acknowledgement of receipt of this assignment:

Attorney Docket Nos.: 50971-044002 50971-044003

Signature

Representative Name:

Shlomi Raz

Representative
Title:

CEO

Eleusis Therapeutics US, Inc.

Witness:

Docussigned by:

July Major

Stgrature AFDD490...

Judit Major

Page 3 of 3